US2016310411A1PendingUtilityA1

Rivastigmine pamoate, memantine pamoate, methods of preparation and uses thereof

52
Assignee: GU ZI-QIANGPriority: Nov 29, 2011Filed: Apr 20, 2016Published: Oct 27, 2016
Est. expiryNov 29, 2031(~5.3 yrs left)· nominal 20-yr term from priority
Inventors:Zi-Qiang Gu
A61P 25/28C07D 211/32A61K 31/445C07C 65/11A61K 9/0019C07C 211/38C07C 271/44A61K 31/13A61K 31/27
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The composition containing a pamoate salt of donepezil, the method of preparation and the use thereof are disclosed.

Claims

exact text as granted — not AI-modified
1 - 5 . (canceled) 
     
     
         6 . A pharmaceutical composition comprising a pamoate salt of rivastigmine and a pharmaceutically acceptable carrier, wherein the carrier is a viscous aqueous or nonaqueous carrier. 
     
     
         7 . (canceled) 
     
     
         8 . A pharmaceutical composition comprising a pamoate salt of rivastigmine and a pharmaceutically acceptable carrier, wherein the composition releases an effective amount of the pamoate salt of rivastigmine over a period of at least about 24 hours. 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the composition releases an effective amount of the pamoate salt of rivastigmine over a period of at least about 48 hours. 
     
     
         10 . The pharmaceutical composition of  claim 8 , wherein the duration of efficacy of the pamoate salt of rivastigmine is at least about 7 days. 
     
     
         11 . The pharmaceutical composition of  claim 8 , wherein the duration of efficacy of the pamoate salt of rivastigmine is at least about 14 days. 
     
     
         12 - 14 . (canceled) 
     
     
         15 . A method of treating an individual having dementia associated with Alzheimer's disease comprising administering a pharmaceutical composition according to  claim 6 . 
     
     
         16 . The method of  claim 15 , wherein the composition is administered by injection. 
     
     
         17 . The method of  claim 15 , wherein the composition is administered intramuscularly or subcutaneously. 
     
     
         18 . A method of treating an individual having dementia associated with Alzheimer's disease comprising administering a pharmaceutical composition according to  claim 8 . 
     
     
         19 . The method of  claim 18 , wherein the composition releases an effective amount of the pamoate salt of rivastigmine over a period of at least about 48 hours. 
     
     
         20 . The method of  claim 18 , wherein the duration of efficacy of the pamoate salt of rivastigmine is at least about 7 days. 
     
     
         21 . The method of  claim 18 , wherein the duration of efficacy of the pamoate salt of rivastigmine is at least about 14 days. 
     
     
         22 - 25 . (canceled) 
     
     
         26 . A pharmaceutical composition comprising a pamoate salt of memantine and a pharmaceutically acceptable carrier, wherein the carrier is a viscous aqueous or nonaqueous carrier. 
     
     
         27 . A pharmaceutical composition comprising a pamoate salt of memantine and a pharmaceutically acceptable carrier, wherein the composition releases an effective amount of the pamoate salt of memantine over a period of at least about 24 hours. 
     
     
         28 . The pharmaceutical composition of  claim 27 , wherein the composition releases an effective amount of the pamoate salt of memantine over a period of at least about 48 hours. 
     
     
         29 . The pharmaceutical composition of  claim 27 , wherein the duration of efficacy of the pamoate salt of memantine is at least about 7 days. 
     
     
         30 . The pharmaceutical composition of  claim 27 , wherein the duration of efficacy of the pamoate salt of memantine is at least about 14 days. 
     
     
         31 . A method of treating an individual having dementia associated with Alzheimer's disease comprising administering a pharmaceutical composition according to  claim 26 . 
     
     
         32 . The method of  claim 31 , wherein the composition is administered by injection. 
     
     
         33 . The method of  claim 31 , wherein the composition is administered intramuscularly or subcutaneously. 
     
     
         34 . A method of treating an individual having dementia associated with Alzheimer's disease comprising administering a pharmaceutical composition according to  claim 27 . 
     
     
         35 . The method of  claim 31 , wherein the composition releases an effective amount of the pamoate salt of memantine over a period of at least about 48 hours. 
     
     
         36 . The method of  claim 34 , wherein the duration of efficacy of the pamoate salt of memantine is at least about 7 days. 
     
     
         37 . The method of  claim 34 , wherein the duration of efficacy of the pamoate salt of memantine is at least about 14 days.

Join the waitlist — get patent alerts

Track US2016310411A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.